Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort. / Egeberg, Alexander; Schlapbach, Christoph; Haugaard, Jeanette Halskou; Nymand, Lea; Thein, David; Thomsen, Simon Francis; Thyssen, Jacob P.
In: JAAD International, Vol. 14, 2024, p. 77-83.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort
AU - Egeberg, Alexander
AU - Schlapbach, Christoph
AU - Haugaard, Jeanette Halskou
AU - Nymand, Lea
AU - Thein, David
AU - Thomsen, Simon Francis
AU - Thyssen, Jacob P.
N1 - Publisher Copyright: © 2023 American Academy of Dermatology, Inc.
PY - 2024
Y1 - 2024
N2 - Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited. Objectives: To investigate patient-reported adverse events to TCS in CHE patients. Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort. We assessed patients’ knowledge about TCS use and adverse event risks, and preference of TCS versus a nonsteroidal topical alternative. Results: Of 724 adults with CHE (64.0% women; mean age 57.5 [standard deviation 12.8] years), 64.1% reported skin atrophy, 41.4% cracks/fissures, 23.9% bleeding, 45.9% pain/stinging sensation, 40.0% reduced hand dexterity, and 40.2% worsening of CHE signs or symptoms from using TCS. We observed CHE-severity-dependent associations (all groups; P <.0001). Most patients (76.4%) would prefer a nonsteroidal option, 10.9% were neutral/indifferent, and 12.7% would prefer TCS for CHE. The median numerical rating scale-score (ranging from 0 to 10) was 10 (interquartile range 6-10) for preferring a nonsteroidal topical treatment. Limitations: Differences across TCS formulations were unexplored. Conclusion: TCS-related cutaneous adverse events were common. There is a desire from patients for novel steroid-free topical alternatives for CHE treatment.
AB - Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited. Objectives: To investigate patient-reported adverse events to TCS in CHE patients. Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort. We assessed patients’ knowledge about TCS use and adverse event risks, and preference of TCS versus a nonsteroidal topical alternative. Results: Of 724 adults with CHE (64.0% women; mean age 57.5 [standard deviation 12.8] years), 64.1% reported skin atrophy, 41.4% cracks/fissures, 23.9% bleeding, 45.9% pain/stinging sensation, 40.0% reduced hand dexterity, and 40.2% worsening of CHE signs or symptoms from using TCS. We observed CHE-severity-dependent associations (all groups; P <.0001). Most patients (76.4%) would prefer a nonsteroidal option, 10.9% were neutral/indifferent, and 12.7% would prefer TCS for CHE. The median numerical rating scale-score (ranging from 0 to 10) was 10 (interquartile range 6-10) for preferring a nonsteroidal topical treatment. Limitations: Differences across TCS formulations were unexplored. Conclusion: TCS-related cutaneous adverse events were common. There is a desire from patients for novel steroid-free topical alternatives for CHE treatment.
KW - adverse events
KW - chronic hand eczema
KW - Danish Skin Cohort
KW - side effects
KW - topical corticosteroids
U2 - 10.1016/j.jdin.2023.11.004
DO - 10.1016/j.jdin.2023.11.004
M3 - Journal article
C2 - 38274394
AN - SCOPUS:85181828746
VL - 14
SP - 77
EP - 83
JO - JAAD International
JF - JAAD International
SN - 2666-3287
ER -
ID: 379654315